Investment House LLC Purchases Shares of 3,000 Elevance Health, Inc. $ELV

Investment House LLC acquired a new stake in Elevance Health, Inc. (NYSE:ELV) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 3,000 shares of the company’s stock, valued at approximately $969,000.

Several other institutional investors also recently modified their holdings of ELV. Vermillion & White Wealth Management Group LLC grew its holdings in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after purchasing an additional 37 shares during the period. BOK Financial Private Wealth Inc. bought a new stake in Elevance Health in the second quarter valued at approximately $32,000. Motco lifted its position in shares of Elevance Health by 334.8% in the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares during the last quarter. True Wealth Design LLC boosted its stake in shares of Elevance Health by 431.8% during the 3rd quarter. True Wealth Design LLC now owns 117 shares of the company’s stock worth $38,000 after acquiring an additional 95 shares during the period. Finally, Glass Jacobson Investment Advisors llc boosted its stake in shares of Elevance Health by 400.0% during the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock worth $39,000 after acquiring an additional 80 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ELV has been the topic of a number of research analyst reports. Barclays increased their price target on Elevance Health from $385.00 to $404.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Robert W. Baird raised their target price on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $431.00 target price on shares of Elevance Health in a report on Tuesday, January 6th. Finally, Bank of America increased their price target on shares of Elevance Health from $330.00 to $370.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Twelve analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $399.63.

Elevance Health Stock Performance

NYSE ELV opened at $370.77 on Monday. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $82.40 billion, a P/E ratio of 15.16, a P/E/G ratio of 1.91 and a beta of 0.51. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The firm has a 50-day moving average price of $349.17 and a two-hundred day moving average price of $328.67.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.